Anti-CD33 CAR T-cells clinical trials
How each study uses Anti-CD33 CAR T-cells is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD33 CAR T-cells studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Anti-CD33 CAR T-cells
- 1
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
City of Hope Medical Center (1) · Zhejiang University (1) · iCell Gene Therapeutics (1)
Often tested with
Tested in the same studies.
Anti-CD33 CAR T Cells Preparation (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD33 CAR T-cells.
- Oct 2027A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaEarly Phase 1 · Zhejiang University
Studies
Open first, then newest update. How each study uses Anti-CD33 CAR T-cells is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid LeukemiaRecruitingPhase 1City of Hope Medical CenterNCT05672147Written as Anti-CD33 CAR T-cellsHow we know
- A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingEarly Phase 1Zhejiang UniversityNCT06762132Written as CD33 CAR T-cellsHow we know
- Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid LeukemiaStatus unknownPhase 1iCell Gene TherapeuticsNCT05445765Written as anti-CD33 CAR T cellsHow we know